Independent business intelligence for the life sciences sector
NEWS

PRESS RELEASE 13th April 2007

Beremans Ltd market research study published in the Journal of Travel Medicine

Beremans Ltd, the Cambridge-based investment research company (www.beremans.com), announced today that data generated in a Beremans market research study have been published in the Journal of Travel Medicine (2007) 14:158-167.

The paper, entitled “Current perceptions of Traveller’s Diarrhoea treatments and vaccines: results from a postal questionnaire survey and physician interviews”, presents an analysis of UK and US physicians’ perceptions of currently available Traveller’s Diarrhoea (TD) products, of hypothesised TD vaccines, and of aspects of travellers’ behaviour pertinent to the travel vaccine market. The study particularly focused on proposed campylobacteriosis vaccines, and the results of the research suggest, inter alia, that an effective Campylobacter vaccine for Traveller’s Diarrhoea might be purchased by over two million travellers per year.

Nearly 70 physicians participated in the survey, representing a population of over 75,000 travellers per year. Results from the study indicate that both UK and US physicians support the concept of TD vaccines, including campylobacteriosis vaccines, and that an ideal TD vaccine might be purchased by up to 16% (UK) and 28% (US) of relevant travellers. The study was supported by ACE Biosciences (www.acebiosciences.com), an emerging pharmaceutical company developing novel, protein-based vaccines and antibodies to address infectious diseases caused by bacteria.

Dr Nicholas Miller, Managing Director of Beremans Ltd, said “Most of our market research studies are bespoke projects that never become public. However, on this occasion, one of our clients, ACE Biosciences, gave permission for aspects of a study to be published, and accordingly we submitted a subset of our data to the Journal of Travel Medicine. We were delighted when the paper was accepted, not least because publication in a leading academic journal is associated with a rigorous peer review process. Therefore, publication not only allows our data to be more widely disseminated, but also confers significant third party validation on our research and methodology.”
Beremans Ltd is a Cambridge-based company that provides due diligence, market research and equity analysis services for the Life Sciences sector.

For further information please email:

Dr. Nicholas Miller, Managing Director, Beremans Ltd: nm01@beremans.com